These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 28323993)
1. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta. Vuorimies I; Mäyränpää MK; Valta H; Kröger H; Toiviainen-Salo S; Mäkitie O J Clin Endocrinol Metab; 2017 Apr; 102(4):1333-1339. PubMed ID: 28323993 [TBL] [Abstract][Full Text] [Related]
2. Do femoral fractures in adult patients with osteogenesis imperfecta imitate atypical femoral fractures? A case series. Andersen JD; Bünger MH; Rahbek O; Hald JD; Harsløf T; Langdahl BL Osteoporos Int; 2019 Feb; 30(2):513-517. PubMed ID: 30448959 [TBL] [Abstract][Full Text] [Related]
3. Diaphyseal Femur Fractures in Osteogenesis Imperfecta: Characteristics and Relationship With Bisphosphonate Treatment. Trejo P; Fassier F; Glorieux FH; Rauch F J Bone Miner Res; 2017 May; 32(5):1034-1039. PubMed ID: 28019684 [TBL] [Abstract][Full Text] [Related]
4. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years. Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976 [TBL] [Abstract][Full Text] [Related]
5. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates. Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924 [TBL] [Abstract][Full Text] [Related]
6. Recurrent Proximal Femur Fractures in a Teenager With Osteogenesis Imperfecta on Continuous Bisphosphonate Therapy: Are We Overtreating? Vasanwala RF; Sanghrajka A; Bishop NJ; Högler W J Bone Miner Res; 2016 Jul; 31(7):1449-54. PubMed ID: 26845496 [TBL] [Abstract][Full Text] [Related]
7. Management of atypical femoral fracture in a patient with osteogenesis imperfecta. Tan JY; Seow CJ BMJ Case Rep; 2017 Dec; 2017():. PubMed ID: 29269360 [TBL] [Abstract][Full Text] [Related]
8. Alendronate treatment in children with osteogenesis imperfecta. Akcay T; Turan S; Guran T; Bereket A Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788 [TBL] [Abstract][Full Text] [Related]
9. Incidence and treatment of adult femoral fractures with osteogenesis imperfecta: An analysis of a center of 72 patients in Taiwan. Lee CL; Liu SC; Yang CY; Chuang CK; Lin HY; Lin SP Int J Med Sci; 2021; 18(5):1240-1246. PubMed ID: 33526985 [No Abstract] [Full Text] [Related]
10. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Nieves JW; Cosman F Curr Osteoporos Rep; 2010 Mar; 8(1):34-9. PubMed ID: 20425089 [TBL] [Abstract][Full Text] [Related]
11. Response to zolendronic acid in children with type III osteogenesis imperfecta. Panigrahi I; Das RR; Sharda S; Marwaha RK; Khandelwal N J Bone Miner Metab; 2010 Jul; 28(4):451-5. PubMed ID: 20131072 [TBL] [Abstract][Full Text] [Related]
12. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta. Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187 [TBL] [Abstract][Full Text] [Related]
13. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective. Shah I; Johari A Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731 [TBL] [Abstract][Full Text] [Related]
14. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. Rauch F; Munns C; Land C; Glorieux FH J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452 [TBL] [Abstract][Full Text] [Related]
15. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study. Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583 [TBL] [Abstract][Full Text] [Related]
16. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy. Sousa T; Bompadre V; White KK J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411 [TBL] [Abstract][Full Text] [Related]
17. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533 [TBL] [Abstract][Full Text] [Related]
18. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638 [TBL] [Abstract][Full Text] [Related]
19. Zoledronate for Osteogenesis imperfecta: evaluation of safety profile in children. Kumar C; Panigrahi I; Somasekhara Aradhya A; Meena BL; Khandelwal N J Pediatr Endocrinol Metab; 2016 Aug; 29(8):947-52. PubMed ID: 27235668 [TBL] [Abstract][Full Text] [Related]
20. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates. Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]